Axial Psoriatic Arthritis: What to Do When Initial Biologic or JAK Inhibitor Therapy Has Not Worked

Clinically relevant axial involvement defines a distinct and often undertreated subset of psoriatic arthritis. When a first-line biologic DMARD or JAK inhibitor has been tried and the expected treatment targets were not reached, a structured switch to the next line of therapy is warranted.

Clinical scenario: Psoriatic arthritis with clinically relevant axial disease — patient has not achieved the required response on an initial bDMARD or JAK inhibitor and is being considered for the next treatment step.

Prior Treatment & Failure Condition

Previous first-line therapy: An IL-17A inhibitor, a TNF inhibitor, an IL-17A/F inhibitor, or a JAK inhibitor — selected as the initial agent for predominantly axial disease.

Targets not reached on that therapy: Improvement at 3 months; remission or low disease activity at 6 months.

Failure to meet these targets is the criterion for escalation to this protocol.

Next-Step Approach

The approach at this stage involves switching to a different biologic DMARD or JAK inhibitor — the full protocol specifies which agent classes apply, whether switching within the same class or across classes, and what sequencing is appropriate for the axial disease context. The complete decision algorithm is available in the structured regimen.

Treatment Targets

The next treatment line aims for measurable improvement at 3 months, with a goal of remission or low disease activity at 6 months. Disease activity should be assessed at regular intervals and therapy adjusted if these targets are not met.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ard-2024-225531

In patients with clinically relevant axial disease with an insufficient response to NSAIDs, therapy with an IL-17A inhibitor, a TNF inhibitor, an IL-17 A/F inhibitor or a JAKi should be considered.

For axial disease, in agreement also with the recently updated ASAS/EULAR axSpA recommendations, we continue to judge csDMARDs as not relevant.

In patients with an inadequate response or intolerance to a bDMARD or a JAKi, switching to another bDMARD or JAKi should be considered, including one switch within a class.

Treatment should be aimed at reaching the target of remission or, alternatively, low disease activity, by regular disease activity assessment and appropriate adjustment of therapy.

View source ↗